drugset
drugset / Trial / NCT01090024

Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids

NCT01090024 ↗

Phase 2 Completed 108 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

To investigate the effectiveness and safety of BI 671800 given in the morning (AM), evening (PM) or twice daily (b.i.d.) compared too placebo as add on therapy to inhaled corticosteroid in symptomatic asthma patients.

Timeline

Start
2010-03-01
Primary completion
2011-02-01
Completion
2011-02-18

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 671800 Small molecule 200 mg Oral
Subject BI 671800 Small molecule 400 mg Oral

Indications

asthma